This site is intended only for Australian Healthcare Professionals
|Lab monitoring recommendations for patients taking XELJANZ1|
|At initiation||After 4 to 8 weeks||Every 3 months thereafter|
|Lipids||After 8 weeks following initiation of therapy|
|Liver enzymes||Routine monitoring of liver test and prompt investigation of the cause of liver enzyme elevation are also recommended|
|Avoid initiating treatment in patients with:||Lymphocyte count <0.75 cells x109/L||Absolute neutrophil count <1.0 cells
|Hemoglobin levels <9 g/dL|
ALT=alanine aminotransferase; AST=aspartate aminotransferase; BID=twice daily; BMI=body mass index; DMARD=disease-modifying antirheumatic drug; HDL=high-density lipoprotein; IL-1R=interleukin-1 receptor; IL-6R=interleukin-6 receptor; LDL=low-density lipoprotein; MTX=methotrexate; RA=rheumatoid arthritis; TB=tuberculosis; TNF=tumor necrosis factor.
See the XELJANZ safety data for PsA
Want to see pivotal data in moderate to severe PsA?
▼This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.
XELJANZ should only be used if no suitable treatment alternatives are available in patients:
See PI for details, Section 4.4 Special Warnings and Precautions for Use: Mortality; Major Adverse Cardiovascular Events (including Myocardial Infarction); Thrombosis; Malignancy and Lymphoproliferative Disorder (excluding Nonmelanoma Skin Cancer [NMSC]); Skin Cancer and Use in the Elderly.
Before prescribing, please review full Product Information available here.
PBS Information: Authority required for the treatment of adults with severe active rheumatoid arthritis and for adults with severe psoriatic arthritis and for adults with moderate-to-severe ulcerative colitis. Refer to the PBS Schedule for full authority information. This product is not listed on the PBS for juvenile idiopathic arthritis, juvenile psoriatic arthritis, or ankylosing spondylitis.
To access further materials, resources and receive communication about Pfizer medicines and vaccines.
The site is intended for Australian healthcare professionals.
©2023 Pfizer Australia Pty Ltd. Sydney, Australia. All rights reserved.